A New Class of Therapeutics

  • Author: Natalia Ortuzar
  • Published: 31 March 2011
  • Copyright: WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
  • Source / Publisher: 241st American Chemical Society National Meeting, Anaheim, CA, USA
thumbnail image: A New Class of Therapeutics

Staple peptides represent a genuinely new frontier in medicine, said Professor Gregory Verdine, Harvard University, USA, when speaking this week at the 241st National Meeting of the American Chemical Society.

Prof. Verdine went on to say that these staple peptides are able to address targets previously considered "undruggable" by conventional therapeutics, such as small-molecule agents. In one advance, a staple peptide was able to target beta-catenin, an aberrant protein implicated in the progression of colon cancer and other types of cancer such as skin, brain and ovarian.

Studies are ongoing to establish the potential of these staple peptides as novel therapeutics.


Other articles related to the ACS meeting

Article Views: 3150

Sign in Area

Please sign in below

Additional Sign In options

Please note that to comment on an article you must be registered and logged in.
Registration is for free, you may already be registered to receive, e.g., the newsletter. When you register on this website, please ensure you view our terms and conditions. All comments are subject to moderation.

Article Comments - To add a comment please sign in

If you would like to reuse any content, in print or online, from ChemistryViews.org, please contact us first for permission and consult our permission guidance prior to making your request

Follow on Facebook Follow on Twitter Follow on YouTube Follow on LinkedIn Follow on Instagram RSS Sign up for newsletters

Magazine of Chemistry Europe (16 European Chemical Societies) published by Wiley-VCH